8 results
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
stratification algorithm ... for the treatment ... thrombosis; PE = pulmonary ... embolism; GI = ... #Management #Hematology
Shock - Differential Diagnosis Framework
 - MAP <65. SBP <90, drop in SBP > 40
 -
- Differential Diagnosis ... • Obstructive: Pulmonary ... Embolism, Tension ... #criticalcare #algorithm ... #treatment #management
Pulmonary Nodule
Evaluation is guided by nodule size & assessment of probability of malignancy. In addition is
Evaluation is guided ... yield of available diagnostic ... The treatment of ... Management options ... of lung cancer.
Pheochromocytoma - Diagnosis and Management Summary
10 percent rule = 10% of pheochromocytomas are extra-adrenal, multiple, bilateral,
Pheochromocytoma - Diagnosis ... bilateral, malignant, pediatric ... may present with pulmonary ... Beta blockers cancel ... #Management #treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
Lymphoma • Lung cancer ... • Septic emboli ... Tuberculosis Diagnosis ... Tuberculosis #TB #Diagnosis ... #Management #Treatment
It is important to recognize Acute Decompensated Heart Failure (ADHF) as more than just simply a
are excellent at evaluating ... with presence of pulmonary ... & Dry) is the treatment ... #algorithm #management ... #cardiology #treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
Lymphoma • Lung cancer ... • Septic emboli ... Tuberculosis Diagnosis ... Tuberculosis #TB #Diagnosis ... #Management #Treatment
Myelodysplastic syndromes current treatment algorithm 2018.

From Blood Cancer Journal, Published 24 May 2018

Myelodysplastic syndromes (MDS) are
syndromes current treatment ... algorithm 2018. ... risk of clonal evolution ... median age at diagnosis ... cardiovascular or pulmonary